Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Apellis Slashes Costs To Focus On Troubled Syfovre Launch

Cuts To Jobs And Pipeline

30 Aug 2023

• By Andrew McConaghie

Apellis — • Source: Apellis

Related Content

Astellas’ Izervay Joins Geographic Atrophy Market, Intensifying Competition

07 Aug 2023

Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns

24 Aug 2023

Related Companies

Apellis Pharmaceuticals, Inc.

Beam Therapeutics Inc.

Astellas Pharma, Inc.

Additional Topics

Restructuring Launches Safety Commercial Companies Research & Development BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.